Introducing our Genomic Profiling Pathway in association with HCA Healthcare UK (HCA)
At AXA PPP healthcare we’re restless for a reason - with the fast paced and innovative nature of developments in cancer treatment, we feel it’s important to keep pace with these changes and help you support your employees by providing new options that may lead to better health outcomes.
As part of this restlessness, we’re delighted to announce the introduction of our “Genomic Profiling Pathway” pilot in association with HCA, which is now available to our clients and members.
This form of genomic profiling, known as “Next Generation Sequencing”, is a new approach that provides a more comprehensive view of the patient’s tumour to inform clinicians when determining future treatment paths.
This personalised approach aims to help identify what drug is likely to be most effective for each individual patient – which could result in the patient being offered participation in a clinical trial, thereby providing access to further treatment options.
Our “Genomic Profiling Pathway” is available to all breast, lung, prostate and colon cancer patients receiving treatment within an HCA hospital, as clinically appropriate.